Sales revenue for FY2025 was \u00a5453.3 billion (up 13.7% YoY), operating income was \u00a5107.3 billion (up 272.6% YoY), and net income attributable to owners of the parent was \u00a5106.9 billion (up 352.2% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4506-20260513-01.pdf","jir_short_summary":"Sales revenue for FY2025 was \u00a5453.3 billion (up 13.7% YoY), operating income was \u00a5107.3 billion (up 272.6% YoY), and net income attributable to owners of the parent was \u00a5106.9 billion (up 352.2% YoY).","jir_summary":"### FY2025 Financial Results Overview\nSales revenue for FY2025 was \u00a5453.3 billion (up 13.7% YoY), operating income was \u00a5107.3 billion (up 272.6% YoY), and net income attributable to owners of the parent was \u00a5106.9 billion (up 352.2% YoY). The increase in sales revenue was driven by the growth of Orgovirx, GemTesa, and the increase in milestone revenue. Selling, general, and administrative expenses decreased due to structural improvements and partial business transfers. Regionally, North America saw significant growth, while Japan declined; overall, both revenue and profit increased.\n\n### FY2026 Performance Forecast and Growth Strategy\nFor FY2026, sales revenue is projected to reach \u00a5540.0 billion (up 19.1% YoY), operating income to \u00a590.0 billion (down 16.2% YoY), and net income attributable to owners of the parent to \u00a577.0 billion (down 27.9% YoY). The revenue growth predominantly stems from the expansion of Orgovirx and GemTesa in North America. Conversely, profit margins are affected by increased R&D expenses, currency exchange impacts, and higher selling expenses. The company emphasizes mid- to long-term growth investments, including fundamental structural reforms, nurturing next-generation growth engines, and strengthening its financial base.","jir_financial_highlights":"Sales Revenue: \u00a5453.3 billion (Up 13.7% YoY)\nOperating Income: \u00a5107.3 billion (Up 272.6% YoY)\nNet Income Attributable to Owners of the Parent: \u00a5106.9 billion (Up 352.2% YoY)\nForecast for FY2026 Sales Revenue: \u00a5540.0 billion (Up 19.1% YoY)\nForecast for FY2026 Operating Income: \u00a590.0 billion (Down 16.2% YoY)\nForecast for FY2026 Net Income Attributable to Owners of the Parent: \u00a577.0 billion (Down 27.9% YoY)","jir_category":"","jir_hashtags":"#SumitomoPharmaceutical, #FinancialResultsBriefing, #JapanStocks","jir_key_figures":"Sales Revenue (FY2025 Actual): \u00a5453.3 billion (up 13.7% YoY)\nOperating Income (FY2025 Actual): \u00a5107.3 billion (up 272.6% YoY)\nNet Income Attributable to Owners of the Parent (FY2025 Actual): \u00a5106.9 billion (up 352.2% YoY)","jir_meta_title":"\u3010Sumitomo Pharma\u3011FY2025 Financial Results\uff5cSales \u00a5453.3 billion (+13.7%), Operating Income \u00a5107.3 billion","jir_meta_description":"Sumitomo Pharma's FY2025 financial results show sales of \u00a5453.3 billion (up 13.7% YoY) and operating income of \u00a5107.3 billion (up 272.6% YoY), with growth. The FY2026 forecast indicates sales of \u00a5540.0 billion, accelerating growth strategy.","jir_og_title":"\u3010Sumitomo Pharma\u3011FY2025 Financial Results\uff5cSales \u00a5453.3 billion (+13.7%), Operating Income \u00a5107.3 billion","jir_og_description":"Sumitomo Pharma's FY2025 financial results show revenue increase and profit growth. The FY2026 outlook projects sales of \u00a5540.0 billion, with continued investment in long-term growth.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Revenue Trend (FY2021\u2013FY2026 Forecast)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales Revenue (billion yen)\\\",\\\"data\\\":[null,null,null,3988,4533,5400],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend (FY2021\u2013FY2026 Forecast)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit (billion yen)\\\",\\\"data\\\":[null,null,null,288,1073,900],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of the Parent Trend (FY2021\u2013FY2026 Forecast)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2021\\\",\\\"2022\\\",\\\"2023\\\",\\\"2024\\\",\\\"2025\\\",\\\"2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (billion yen)\\\",\\\"data\\\":[null,null,null,236,1069,770],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Major Product Sales Revenue (North America & Japan) (FY2025)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Orgovirx\\\",\\\"GemTesa\\\",\\\"MyFenBree\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"North America (billion yen)\\\",\\\"data\\\":[1550,960,144,80],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"Japan (billion yen)\\\",\\\"data\\\":[137,32,106,226],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Actual Results (FY2025) and Forecast (FY2026)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Sales Revenue\\\",\\\"Operating Income\\\",\\\"Net Income\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Actual FY2025 (billion yen)\\\",\\\"data\\\":[4533,1073,1069],\\\"backgroundColor\\\":\\\"#6c757d\\\"},{\\\"label\\\":\\\"Forecast FY2026 (billion yen)\\\",\\\"data\\\":[5400,900,770],\\\"backgroundColor\\\":\\\"#17a2b8\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48810","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n